Takeda’s cancer prospects dim further
After trimming its cell therapy pipeline last year, the group is now out entirely.
After trimming its cell therapy pipeline last year, the group is now out entirely.
Orca-T is said to hit in a pivotal trial, but the comparator regimen could be debated.
Just when investors thought things couldn't get any worse, they do.
Galapagos distances itself from Gilead, and offers a pure-play oncology cell therapy focus.
The company’s TARA-002 produces competitive results in BCG-unresponsive bladder cancer, albeit in just five patients.
The depressed company could use Mylotarg as a stepping stone in AML.
The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.